Exendin-4 prevents c-Jun N-terminal protein kinase activation by Tumor Necrosis Factor-α (TNFα) and inhibits TNFα-induced apoptosis in insulin-secreting cells

Endocrinology

Volumn 151, Issue 5, 2010, Pages 2019-2029

  Natalicchio, Annalisa ^a   De Stefano, Francesca ^a   Orlando, Maura Roberta ^a   Melchiorre, Mariangela ^a   Leonardini, Anna ^a   Cignarelli, Angelo ^a   Labarbuta, Rossella ^a   Marchetti, Piero ^b   Perrini, Sebastio ^a   Laviola, Luigi ^a   Giorgino, Francesco ^a  

^a UNIVERSITY OF BARI   (Italy)

^b Azienda Ospedaliera Universitaria Pisa   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIC AMP DEPENDENT PROTEIN KINASE; EXENDIN 4; I KAPPA B ALPHA; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PROTEIN BCL 2; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; ANTIDIABETIC AGENT; I KAPPA B; INSULIN RECEPTOR SUBSTRATE; ISOQUINOLINE DERIVATIVE; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; PEPTIDE; PROTEIN KINASE INHIBITOR; SERINE; SULFONAMIDE; VENOM;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; INSULINOMA; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN PHOSPHORYLATION; RAT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IMMUNOBLOTTING; METABOLISM; PHOSPHORYLATION; TIME; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; ENZYME ACTIVATION; HUMANS; HYPOGLYCEMIC AGENTS; I-KAPPA B PROTEINS; IMMUNOBLOTTING; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN-SECRETING CELLS; ISOQUINOLINES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SERINE; SULFONAMIDES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VENOMS;

EID: 77953148018     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-1166     Document Type: Article

References (56)

1. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC 2003 β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110
2. Donath MY, Størling J, Maedler K, Mandrup-Poulsen T 2003 Inflammatory mediators and islet β-cell failure: a link between type 1 and type 2 diabetes. J Mol Med 81:455-470
3. Stephens LA, Thomas HE, Ming L, Grell M, Darwiche R, Volodin L, Kay TW 1999 Tumor necrosis factor-α-activated cell death pathways in NIT-1 insulinoma cells and primary pancreatic β-cells. Endocrinology 140:3219-3227
4. Ishizuka N, Yagui K, Tokuyama Y, Yamada K, Suzuki Y, Miyazaki J, Hashimoto N, Makino H, Saito Y, Kanatsuka A 1999 Tumor necrosis factor α signaling pathway and apoptosis in pancreatic β-cells. Metabolism 48:1485-1492
5. Chen G, Goeddel DV 2002 TNF-R1 signaling: a beautiful pathway. Science 296:1634-1635
6. Davis RJ 2000 Signal transduction by the JNK group of MAP kinases. Cell 103:239-252
7. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA, Davis RJ 2000 Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288:870-874
8. Yang DD, Kuan CY, Whitmarsh AJ, Rincón M, Zheng TS, Davis RJ, Rakic P, Flavell RA 1997 Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 389:865-870
9. Lin A, Minden A, Martinetto H, Claret FX, Lange-Carter C, Mercurio F, Johnson GL, Karin M 1995 Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science 268:286-290
10. 2-terminal kinase. Mol Cell Biol 22:4929-4942
11. 307. J Biol Chem 275:9047-9054
12. Kaneto H, Xu G, Fujii N, Kim S, Bonner-Weir S, Weir GC 2002 Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. J Biol Chem 277:30010-30018
13. Abdelli S, Abderrahmani A, Hering BJ, Beckmann JS, Bonny C 2007 The c-Jun N-terminal kinase JNK participates in cytokine- and isolation stress-induced rat pancreatic islet apoptosis. Diabetologia 50: 1660-1669
14. Drucker DJ 2002 Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122:531-544 (Pubitemid 34117003)
15. Giorgino F, Natalicchio A, Leonardini A, Laviola L 2007 Exploiting the pleiotropic actions of GLP-1 for the management of type 2 diabetes mellitus and its complications. Diabetes Res Clin Pract 78(Suppl 1):S59-S67
16. Tang-Christensen M, Larsen PJ, Thulesen J, Rømer J, Vrang N 2000 The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 6:802-807
17. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, Egan JM 2000 Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49:741-748
18. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ 2003 Glucagon-like peptide-1 receptor signaling modulates β-cell apoptosis. J Biol Chem 278:471-478
19. Brubaker PL, Drucker DJ 2004 Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145:2653-2659
20. Tews D, Werner U, Eckel J 2008 Enhanced protection against cytokine-and fatty acid-induced apoptosis in pancreatic β-cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues. Horm Metab Res 40:172-180
21. Blandino-Rosano M, Perez-Arana G, Mellado-Gil JM, Segundo C, Aguilar-Diosdado M 2008 Anti-proliferative effect of pro-inflammatory cytokines in cultured β-cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide-1. J Mol Endocrinol 41:35-44
22. Kwon G, Pappan KL, Marshall CA, Schaffer JE, McDaniel ML 2004 cAMP dose-dependently prevents palmitate-induced apoptosis by both protein kinase A- and cAMP-guanine nucleotide exchange factor-dependent pathways in β-cells. J Biol Chem 279:8938-8945
23. Hui H, Nourparvar A, Zhao X, Perfetti R 2003 Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144: 1444-1455
24. Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker PL 2004 Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 β-cells. Diabetologia 47:478-487
25. Masini M, Bugliani M, Lupi R, del Guerra S, Boggi U, Filipponi F, Marselli L, Masiello P, Marchetti P 2009 Autophagy in human type 2 diabetes pancreatic beta cells. Diabetologia 52:1083-1086
26. Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA 1995 Phosphorylation of human IκB-α on serines 32 and 36 controls IκB-α proteolysis and NF-κB activation in response to diverse stimuli. EMBO J 14:2876-2883
27. Swaroop N, Chen F, Wang L, Dokka S, Toledo D, Rojanasakul Y 2001 Inhibition of nuclear transcription factor-κB by specific IκB kinase peptide inhibitor. Pharm Res 18:1631-1633 (Pubitemid 33022422)
28. 2-terminal kinase pathway. Diabetes 57:1205-1215
29. de Alvaro C, Teruel T, Hernandez R, Lorenzo M 2004 Tumor necrosis factor α produces insulin resistance in skeletal muscle by activation of inhibitor κB kinase in a p38 MAPK-dependent manner. J Biol Chem 279:17070-17078
30. Rabinovitch A, Sumoski W, Rajotte RV, Warnock GL 1990 Cytotoxic effects of cytokines on human pancreatic islet cells in monolayer culture. J Clin Endocrinol Metab 71:152-156 (Pubitemid 120020262)
31. Li G, Barrett EJ, Barrett MO, Cao W, Liu Z 2007 Tumor necrosis factor-α induces insulin resistance in endothelial cells via a p38 mitogen-activated protein kinase-dependent pathway. Endocrinology 148:3356-3363
32. Hotamisligil GS, Shargill NS, Spiegelman BM 1993 Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259:87-91
33. 2-terminal kinase (JNK) pathway during islet transplantation and prevention of islet graft loss by intraportal injection of JNK inhibitor. Diabetologia 50:612-619
34. Fornoni A, Pileggi A, Molano RD, Sanabria NY, Tejada T, Gonzalez-Quintana J, Ichii H, Inverardi L, Ricordi C, Pastori RL 2008 Inhibition of c-jun N terminal kinase (JNK) improves functional β-cell mass in humanislets and leads to AKT and glycogen synthase kinase-3 (GSK-3) phosphorylation. Diabetologia 51:298-308
35. Chin-Chance CV, Newman MV, Aronovitz A, Blomeier H, Kruger J, Lee EJ, Lowe Jr WL 2006 Role of the mitogen-activated protein kinases in cytokine-mediated inhibition of insulin gene expression. J Investig Med 54:132-142
36. 2-terminal kinase activity in insulin-secreting cells: evidence for cytoplasmic restriction. Diabetes 50:2721-2728
37. 2-terminal kinase signaling. Diabetes 52:2497-2502
38. Egefjord L, Jensen JL, Bang-Berthelsen CH, Petersen AB, Smidt K, Schmitz O, Karlsen AE, Pociot F, Chimienti F, Rungby J, Magnusson NE 2009 Zinc transporter gene expression is regulated by pro-inflammatory cytokines: a potential role for zinc transporters in β-cell apoptosis? BMC Endocr Disord 9:7
39. Tews D, Lehr S, Hartwig S, Osmers A, Paslack W, Eckel J 2009 Anti-apoptotic action of exendin-4 in INS-1 β-cells: comparative protein pattern analysis of isolated mitochondria. Horm Metab Res 41:294-301
40. Jacobsen ML, Rønn SG, Bruun C, Larsen CM, Eizirik DL, Mandrup-Poulsen T, Billestrup N 2009 IL-1 β-induced chemokine and Fas expression are inhibited by suppressor of cytokine signalling-3 in insulinproducing cells. Diabetologia 52:281-288
41. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS 2002 A central role for JNK in obesity and insulin resistance. Nature 420:333-336
42. Nakatani Y, Kaneto H, Kawamori D, Hatazaki M, Miyatsuka T, Matsuoka TA, Kajimoto Y, Matsuhisa M, Yamasaki Y, Hori M 2004 Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 279:45803-45809
43. Briaud I, Dickson LM, Lingohr MK, McCuaig JF, Lawrence JC, Rhodes CJ 2005 Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in β-cells. J Biol Chem 280:2282-2293
44. Song WJ, Schreiber WE, Zhong E, Liu FF, Kornfeld BD, Wondisford FE, Hussain MA 2008 Exendin-4 stimulation of cyclin A2 in β-cell proliferation. Diabetes 57:2371-2381
45. Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, Prentki M 2001 Protein kinase Cζ activation mediates glucagon-like peptide-1-induced pancreatic β-cell proliferation. Diabetes 50:2237-2243
46. Cornu M, Yang J, Jaccard E, Poussin C, Widmann C, Thorens B 2009 Glucagon-like peptide-1 protects β-cells against apoptosis by increasing the activity of an IGF-2/IGF-1 receptor autocrine loop. Diabetes 58:1816-1825
47. Liu Z, Habener JF 2008 Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic β-cell proliferation. J Biol Chem 283:8723-8735
48. Perfetti R, Zhou J, Doyle ME, Egan JM 2000 Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141:4600-4605
49. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R 2003 Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144: 5149-5158
50. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M 2004 Glucagon-like peptide-1 prevents β-cell glucolipotoxicity. Diabetologia 47:806-815
51. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R 2002 Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143: 4397-4408
52. Bregenholt S, Møldrup A, Blume N, Karlsen AE, Nissen Friedrichsen B, Tornhave D, Knudsen LB, Petersen JS 2005 The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro. Biochem Biophys Res Commun 330:577-584
53. Li L, El-Kholy W, Rhodes C, Brubaker PL 2005 Glucagon-like peptide-1 protects β-cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia 48:1339-1349 (Pubitemid 41186100)
54. Sarkar SA, Gunter J, Bouchard R, Reusch JE, Wiseman A, Gill RG, Hutton JC, Pugazhenthi S 2007 Dominant negative mutant forms of the cAMP response element binding protein induce apoptosis and decrease the anti-apoptotic action of growth factors in human islets. Diabetologia 50:1649-1659
55. Jhala US, Canettieri G, Screaton RA, Kulkarni RN, Krajewski S, Reed J, Walker J, Lin X, White M, Montminy M 2003 cAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2. Genes Dev 17:1575-1580
56. Doggett TA, Swarthout JT, Jefcoat Jr SC, Wilhelm D, Dieckmann A, Angel P, Partridge NC 2002 Parathyroid hormone inhibits c-Jun N-terminal kinase activity in rat osteoblastic cells by a protein kinase A-dependent pathway. Endocrinology 143:1880-1888